Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Business

Moderna Partners with AWS to Explore the ‘Software of Life’

The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.

January 16, 2020

2 min read

Alex Keown

Drug Development

Moderna Sees Potential Blockbuster in Investigational Vaccine for Disease That Can Cause Birth Defects

Moderna Therapeutics is inching closer to becoming a commercial company and the company sees a potential blockbuster in an experimental treatment.

January 10, 2020

2 min read

Alex Keown

Pharm Country

JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation

It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.

January 9, 2020

5 min read

Mark Terry

Business

BioSpace Movers & Shakers, Sept. 6

Biopharma companies strengthen the C-suite and board of directors with these appointments.

September 5, 2019

7 min read

Alex Keown

BioForest

Losing the War on Antibiotic-Resistant Infections Because of Market Forces

There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?

July 19, 2019

4 min read

Mark Terry

Pharm Country

Clinical Catch-up from Last Week: May 5-10

Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.

May 10, 2019

7 min read

Mark Terry

Drug Development

Moderna Publishes Influenza Vaccine Clinical Trial Data

Cambridge, Mass.-based Moderna announced publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0. They were both published in the journal Vaccine.

May 10, 2019

3 min read

Mark Terry

Drug Development

Highlights: American Society of Gene & Cell Therapy Meeting

The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.

May 3, 2019

4 min read

Mark Terry

Drug Development

Moderna’s Q4 Shows a Company Bursting at the Seams With Activity

Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.

March 6, 2019

3 min read

Mark Terry

JOBS